Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell Therapy
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Seeking Alpha / 11 hours ago 2 Views
Regulatory Milestone Adds to Fast-Track Designation Providing Further Potential Regulatory Advantages as Company Develops First-in-Class Mitochondrial Cell Therapy
Comments